Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Pharmacodynamics, Efficacy, and Pharmacokinetics of TIMP-GLIA in Subjects With Well-controlled Celiac Disease Undergoing Oral Gluten Challenge

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled Study of the Safety, Pharmacodynamics, Efficacy, and Pharmacokinetics of TIMP-GLIA in Subjects With Well-controlled Celiac Disease Undergoing Oral Gluten Challenge

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TAK 101 (Primary)
  • Indications Coeliac disease
  • Focus Pharmacodynamics; Proof of concept
  • Sponsors Cour Pharmaceutical Development

    • Most Recent Events

    • 12 Mar 2021 Results of phase 1 and phase 2a studies assessing safety, tolerability, pharmacokinetics, and efficacy of TAK-101 from the induction of gliadin specific T-cell tolerance in patients with biopsy confirmed CeD, published in the Gastroenterology.
    • 19 May 2020 Results published in Gastroenterology in conjunction with Digestive Disease Week 2020
    • 22 Oct 2019 According to a Takeda media release, data was presented today as a late-breaking abstract at UEG Week 2019, Barcelona, Spain.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top